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The article discusses the most important causes of bladder cancer, related to lifestyle (smoking, diet) and exposure to 
carcinogenic substances, and presents available chemoprevention strategies. Based on the current state of knowledge, 
it enumerates the factors of proven and potential role in reducing the incidence rate of the disease.
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Introduction
Bladder cancer is the most frequent urinary tract cancer 
and ninth among the most commonly diagnosed tumors. 
As many as 330,000 new cases are recorded worldwide each 
year and annual mortality equals 130,000 [1, 2]. Approxima-
tely 2.7 million people currently suffer from the disease [2, 3]. 
According to the statistics kept by the US National Can-
cer Institute, bladder cancer is the fifth most common cancer 
in the country. It is estimated that as many as 74,000 people 
will be diagnosed with the disease in the US in 2015 and 
16,000 of these will die. Bladder cancer is usually diagno-
sed between the age of 75 and 84, and affects men more 
frequently than women [3]. 
Transitional cell carcinoma (TCC) is the dominant hi-
stological type of bladder cancer; it accounts for 90% of all 
cases, 70% of which are benign (non-muscle-invasive blad-
der cancer, NMIBC), and 30% malignant (muscle-invasive 
bladder cancer, MIBC) [4]. However, within 5 years from the 
first appearance of symptoms that suggest the presence of 
a tumor, approximately 40% of benign (NMIBC) cases will 
transition to the invasive type [5].
An important role in the development of bladder cancer 
is usually attributed to external risk factors. The most impor-
tant among these include tobacco smoking, occupational 
exposure to toxins (e.g. 2-naphthylamine, 4-aminobiphenyl, 
4-nitrobiphenyl, benzidine, aniline pigments, soot), and fac-
tors related to diet and lifestyle (fluid intake, calorie intake, 
fat content in diet). A diet rich in fruits, vegetables, and poly-
phenols found in green tea, as well as vitamins and minerals 
is generally considered as a positive lifestyle factor [6, 7].
The purpose of the article is to survey the existing lite-
rature on bladder cancer prophylaxis. It proposes to discuss 
the main risk factors of the disease and the basic principles 
of prevention (Tab. I).
Tobacco smoking 
Studies conducted by various teams around the world 
have established a clear link between smoking and an in-
creased risk of bladder cancer; smoking status has also been 
shown to play an important role, with past smokers less 
likely to suffer from the disease. Smoking is now conside-
red as the single most important exogenous risk factor for 
bladder cancer, associated with approximately 50% of all 
diagnosed cases [8]. The risk for smokers is around three 
times greater than for non-smokers, and quitting tobacco 
serves to reduce the likelihood of the disease by 30 to 60% 
within the next 4 years [9, 10]. The number of cigarettes per 
day also has a significant impact on incidence rate; for those 
who smoke more than two packs (40 cigarettes) per day, the 
risk of bladder cancer is more than four times greater. Studies 
also suggest a correlation with smoking history (a history of 
40 years and more is associated with a fivefold increase in 
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cancer risk) and preferred cigarette type (cigarettes without 
filter are associated with a greater incidence rate) [11, 12]. 
In a study published in 2014, Wyszyński et al. emphasize 
the positive impact of tobacco cessation on preventing the 
progression or relapse of bladder cancer in previously dia-
gnosed patients [13]. Smokers are at a greater risk of cancer 
because of their exposure to chemical compounds typically 
found in tobacco smoke, such as 4-aminobiphenyl, acrolein, 
and free oxygen radicals [6]. The greatest role, however, 
is attributed to aromatic amines. The precise mechanism 
through which these substances impact carcinogenesis has 
not been explained, but it is thought to be related to the 
carbocations released in the bladder during the partial hy-
drolysis of the products of phase II biotransformation, which 
are excreted in urine. Studies conducted in previous decades 
have confirmed their genotoxicity, showing that they are 
able to create DNA adducts and thus induce mutagenesis. 
Other (alternative or additional) carcinogenic effects of aro-
matic amines have also been proposed, including epigenetic 
mechanisms such as abnormal DNA methylation, chromatin 
remodeling, and histone modification [14]. 
Occupational factors 
Occupational exposure has been the most frequently 
studied risk factor for bladder cancer [15]. It is estimated 
to account for 5.3% of all diagnosed cases and 7.1% of 
those found in men [16]. The most important industrial 
chemical compounds implicated in the process of carcino-
genesis include aromatic amines (e.g. 2-naphthyloamine, 
4-aminobiphenyl, 4,4’-methylenedianiline, 4-nitrobiphenyl, 
benzidine), PAHs (e.g. naphthalene, benzo(a)pyrene), coal 
tar, aniline pigments (e.g. methoxyaniline, methoxy-nitro-
aniline), polychlorinated dibenzodioxins, dibenzofuran, 
and chlorinated aliphatic hydrocarbons [7, 17, 18]. A major 
role is also played by metals such as arsenic, cadmium, 
chromium, and nickel [18]. Cumberbatch et al. performed 
a metaanalysis focused on the incidence of bladder cancer 
in various occupational groups; the data indicated a highly 
specific occupational profile of patients exposed to chemical 
carcinogens. The highest risk of bladder cancer is reported 
in individuals working with aromatic amines, while the hi-
ghest mortality rate is observed in those exposed to PAHs 
and heavy metals [18]. Even though social awareness of the 
importance of workplace hygiene is growing and appropria-
te measures are being taken, the reduction of occupational 
exposure to carcinogenic compounds continues to be an 
important element of bladder cancer prevention.
Environmental factors
Arsenic is a metal that occurs naturally in water, soil, and 
air. Found in organic and inorganic form, it is widespread in 
the environment, present in more than 160 different miner-
als, and realeased into the air, for instance, in the process of 
metal ore extraction. Food produced in the vicinity of copper 
mines tends to be contaminated with arsenic compounds. 
The intensive use of arsenic-based herbicides and defoliants 
has also considerably contributed to environmental pollu-
tion. The carcinogenic impact of arsenic on the human body 
has not been fully explained but the substance is known to 
disrupt the homeostasis of metals and SH groups, negatively 
affect DNA methylation, cause oxidative stress, and induce 
cell proliferation [19]. Inorganic arsenic compounds found 
in potable groundwater are commonly recognized as car-
cinogens implicated in the development of lung and skin 
cancer [20], and the World Health Organization recommends 
that their concentration in drinking water should not exceed 
10 mg/L [21]. Studies conducted in Argentina [22], Chile [23], 
USA [24], and Taiwan [25] have linked contamination with 
arsenic to the development of bladder cancer at concentra-
tions of > 0.2 mg/L of drinking water [22–25]. 
Other factors implicated in bladder cancer also included 
bladder infections with Schistosoma haematobium, a major 
agent of schistosomiasis. Research thus far suggests that 
infections with the parasite are particularly common in men 
in developing countries, such as Turkey and Egypt [26, 27].
Diet 
Daily fluid intake
The results of epidemiological studies on the relation-
ship between fluid intake and the risk of bladder cancer thus 
far are inconclusive [28–32].
By increasing the frequency of urination and urine vo-
lume, large fluid intake is thought to reduce the time of 
contact between toxins and the walls of the bladder, thus 
lowering cancer risk [28]. On the other hand, drinking water 
and other beverages may be contaminated with potentially 
Table I. Strategies of the chemoprevention of bladder cancer 
Factors with a proven role Factors with a potential role
Quitting cigarettes and other tobacco products
Reducing occupational exposure to toxins [aromatic amines and 
policyclic aromatic hydrocarbons (PAHs)]
Reducing exposure to arsenic compounds in drinking water
Using non-steroidal anti-inflammatory drugs (NSAIDs), especially 
selective cyclooxygenase-2 (COX-2) inhibitors
Increased intake of polyphenols
Increased intake of clean drinking water
Increased intake of fruits and vegetables
Increased intake of vitamins A, C, E
Reduced intake of fats and high-calorie foods
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carcinogenic compounds such as arsenic or chlorination 
products. Consuming large quantities of such fluids incre-
ases the urine concentration of toxins; as a result, these are 
able to penetrate deeper into the walls of the bladder and 
form mutagenic DNA adducts [29, 30].
A prospective cohort study on a group of 47,909 people 
showed that an increased daily intake of fluids is associated with 
a lower risk of bladder cancer. Subjects who consumed more 
fluids (> 2531 mL/day) were half as likely to develop bladder 
cancer than those who consumed less (< 1290 mL/day) [30]. 
A study of 427 nurses also demonstrated a positive 
impact of high fluid intake on reducing the risk of bladder 
cancer in smokers (the risk dropped by 38%), as well as 
lowering the likelihood of its invasive variety [29].
The European Prospective Investigation into Cancer and 
Nutrition (EPIC), which studied the relationship between 
the quantity and type of consumed fluids and the risk of 
bladder cancer, however, failed to establish any correlation 
between the two variables [31]. Wang et el., on the other 
hand, showed that an increase in total fluid intake correlates 
with a 41% increase in the risk of disease [32].
The precise role of fluid intake in bladder cancer pre-
vention is further confounded by the diversity of beverages 
that may have a different impact on the processes of carci-
nogenesis. The most frequently listed drinks include water, 
tea, coffee, and alcohol [28]. Studies thus far indicate the 
protective effects of water, tea, wine, and milk [28, 31, 32]. 
Data on coffee are inconclusive. It may have a positive im-
pact because of its high polyphenol content, but may also 
be harmful because of the presence of acrylamide [28, 33]. 
These discrepancies require further investigation.
Fat intake
Evidence concerning the relationship between the amo-
unt and type of dietary fat and the risk of bladder cancer is 
limited and inconclusive. This is mostly due to the lack of 
adequate epidemiological data. Studies conducted in the 
1990s in Spain and Sweden found a direct link between the 
consumption of saturated fatty acids of animal origin and 
a  greater risk of bladder cancer [34, 35]. Similar findings 
were obtained in Belgian studies, which also confirmed that 
a Mediterranean diet (rich in olive oil) plays an important 
role in reducing the incidence of the disease [36]. A final 
metaanalysis of 36 epidemiological studies demonstrated 
the positive impact of unsaturated vegetable fats on the 
reduction of bladder cancer risk [37].
Fruits and vegetables
Due to their high concentration of vitamins, minerals, fi-
ber, and other bioactive compounds with anti-carcinogenic 
properties, fruits and vegetables are universally recognized 
as a means of preventing many types of cancer (e.g. of the 
stomach, liver, and intestine). Their beneficial role is related 
to a positive impact they exert on the immune system, their 
strong antioxidative properties, and their ability to reduce 
DNA damage associated with oxidative stress [38]. 
A metaanalysis published in 2014 confirmed the role 
of fruits and vegetables in the reduction of bladder cancer 
risk [39]; the findings of Park et al., however, suggest that 
their intake may only lower cancer incidence in women [40]. 
A metaanalysis performed by Xu et al. only confirmed the 
beneficial effects of green leafy vegetables [38]. Studies 
conducted by EPIC and Vieira et al., on the other hand, 
showed no correlation between fruit and vegetable intake 
and bladder cancer risk [41, 42]. Because of the limited ava-
ilable data, further research is also required on the impact 
of individual fruits and vegetables.
Dietary polyphenols 
Green tea is one of the most frequently consumed be-
verages in the world. Studies conducted on cell lines and 
animal models have demonstrated the strong chemoprotec-
tive properties associated with its high polyphenol content 
[43, 44]. The link between green tea and the reduced risk of 
many cancers is common knowledge, and successive studies 
have confirmed its beneficial properties. Green tea contains 
polyphenolic compounds, such as flavanols, flavonoids, pro-
anthocyanidins, and phenolic acids. Most of these polyphe-
nols belong to catechins (also known as flavonols), which 
are the main component of green tea. Catechins present 
in green tea leaves include: epicatechin (EC), epicatechin 
gallate (ECG), epigallocatechin (EGC), and epigallocatechin 
gallate (EGCG), which is especially abundant [43]. 
In a study on animal models, green tea polyphenols 
were shown to inhibit the development of bladder cancer 
induced by a nitrosamine derivative [45]. In a study of mice 
with subcutaneously implanted bladder cancer cells, epi-
gallocatechin gallate exhibited proapoptotic properties, 
thus impeding cancer growth. The apoptotic process in 
this case is thought to involve the activation of a caspase 
cascade regulated by proteins from the BcL-2 family [46]. 
A study on human bladder cancer cells also confirmed the 
antiproliferative properties of epigallocatechin gallate, 
and polyphenon 60, epicatechin gallate, and the green tea 
extract were shown to have similar proapoptotic effects [44]. 
Zhou et al. studied the pomegranate extract (Punica 
granatum L.) and demonstrated the beneficial, proapoptotic 
impact of pomegranates on human bladder cancer cells. Not 
unlike in the case of green tea, these properties are linked 
to its high polyphenol content, which hinders cancer cell 
proliferation by activating the caspase cascade [47]. 
Literature also indicates the beneficial properties of 
curcumin (another polyphenol) in the prevention of bladder 
cancer. The mechanism involved in this case is related to the 
role of the spice in inducing the expression of a cytoprotec-
tive enzyme, heme oxygenase-1 [48]. 
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Resveratrol, a polyphenol found especially in red grapes, 
is also recognized as a chemoprotective and anticarcinogen-
ic agent. In a study by Stocco et al., high concentrations of 
the substance (> 25 mM) induced the apoptosis of human 
bladder cancer cells (ECV304) [49].
Vitamins and minerals
Vitamins, especially vitamin A, C, and E, are well known 
for their anti-oxidative properties. Numerous studies thus far 
have shown that they likely protect cells against oxidative 
DNA damage by neutralizing free radicals [50]. An increased 
dietary intake of vitamins A, C, E also seems to have a positive 
impact on bladder cancer risk. 
Vitamin C
Vitamin C (ascorbic acid) is an antioxidant involved in 
the maintenance of a healthy redox potential within cells, 
for instance, through the neutralization of reactive oxygen 
species produced during cell metabolism [51]. Shibata et 
al. demonstrated a positive impact of vitamin C supple-
mentation on the reduction of bladder cancer risk [52], but 
subsequent analyses of ascorbic acid concentrations in the 
blood of bladder cancer patients failed to confirm its role in 
the prevention of the disease [51, 52]. 
Vitamin E 
Vitamin E consists of four tocopherols (a, b, g, d). In 
the human body, its most dominant and active form is 
α-tocopherol, involved in neutralizing free oxygen radi-
cals; the substance shows strong antioxidative properties, 
inhibiting the growth of cancer cells and stimulating their 
apoptosis [54]. A study published in 2008 indicated that 
α-tocopherol may have a protective effect in tobacco smok-
ers [54]. Findings of various epidemiological studies also 
confirm the beneficial impact of vitamin E supplementation 
on reducing bladder cancer risk [53].
Vitamin A
Vitamin A and retinol (the most important among the 
retinoids) play a vital role in cell proliferation and differ-
entiation [55]. Data published in 2014 indicate that an in-
creased dietary intake of vitamin A is associated with a lower 
incidence of bladder cancer. A significant risk reduction 
was associated mainly with a-carotene, b-carotene, and 
b-cryptoxanthin [55]. The synthetic retinoid fenretinide 
(N-(4-hydroxyphenyl)retinamide) was also shown to have 
a protective effect in chemically induced bladder cancer 
in animals [56]. 
Other factors
Literature also indicates the beneficial effect of lycopenes 
found in tomato juice, linoleic acid derived from plant oils, 
and betulinic acid isolated from the bark of birch trees [57].
High-calorie foods and a reduced intake of selenium, 
on the other hand, were shown to increase the risk of the 
disease [6, 58]. 
Other factors that may affect the risk of bladder cancer 
include obesity, lack of physical exercise [59], and stress, 
but further research is required to establish the precise 
correlation.
Non-steroidal anti-inflammatory drugs
Numerous experimental, epidemiological, and clinical 
studies have demonstrated the important role of non-ste-
roidal anti-inflammatory drugs (NSAIDs) in the prevention 
of human cancer. This is due to their inhibiting effect on 
the activity of cyclooxygenase-2 (COX-2), which lowers the 
production of prostaglandin E2 [60]. 
A controlled clinical study on 330 patients showed 
a 20% decrease in the incidence of bladder cancer among 
subjects treated with nonsteroidal anti-inflammatory 
drugs. A particularly significant risk reduction (43%) was 
observed for non-smokers [61]. Experiments on mice with 
bladder cancer induced by N-butyl-N-(4-hydroxybutyl)ni-
trosamine (BNN) demonstrated that rofecoxib (a selective 
COX-2 inhibitor) caused a considerable decrease in the 
incidence of precancerous lesions and tumors [62]. The 
effects for meloxicam were not statistically significant [63]. 
The anticarcinogenic properties of meloxicam, however, 
were further tested on three human cell lines of bladder 
cancer and shown to significantly increase DNA damage 
in cancer cells and inhibit their proliferation [63]. The pro-
apoptotic role of celecoxib is associated with its ability to 
induce the autophagy of cancer cells [64]. Other data have 
also shown that naproxen has a beneficial role to play in 
BNN-induced bladder cancer [65]. 
Mesna (sodium 2-mercaptoethanesulfonate)
An important factor with a clinically proven role in in-
creasing the incidence of bladder cancer is therapy with 
cyclophosphamide, an immunosuppressive drug that inhi-
bits cell division. Animal studies show that the risk of cyclo-
phosphamide-induced bladder cancer is significantly lower 
when the treatment is accompanied by the administration 
of Mesna (sodium 2-mercaptoethanesulphonate) [66]. 
Detoxification processes
Considering the role of chemical risk factors in the de-
velopment of bladder cancer, it is crucial to take preventive 
measures to increase the body’s ability to detoxify. Toxic 
elements are largely excreted in urine, following the reac-
tions of phase I and II biotransformation, which means that 
inducing phase II enzymes, such as glutathione S-transfe-
rase (GST), or glutamylcysteine synthetase (GCS) may have 
a beneficial, protective role to play in the prevention of 
bladder cancer.
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The gene polymorphism of glutathione S-transferase 
(GST) may determine individual susceptibility to bladder 
cancer. The risk of disease has been shown to be four times 
greater in individuals with the homozygotic variant of the 
GSTP1 Val/Val genotype [67]. A metaanalysis published by 
Huang et al. confirmed an important increase in cancer 
risk in people with the GSTP1 313A>G polymorphism [68].
And thus, from the toxicological point of view, an im-
portant role in the prevention of bladder cancer is played by 
a specific pool of endogenous compounds that participate 
in phase II detoxification reactions, the activity of selected 
enzymes, and the participation of high-energy compounds 
(e.g. ATP) necessary for activating the endogenous substan-
ces that enable their conjugation. 
Conclusions
Bladder cancer is one of the more frequent urinary tract 
conditions and its development, alongside genetic deter-
minants, is largely related to exogenous factors. Identifying 
these variables allows us to successfully eliminate them and 
thus prevent the incidence of new cases. Examples cited in 
this paper demonstrate the crucial importance of quitting 
tobacco and reducing exposure to carcinogenic substances 
(such as aromatic amines, polycyclic aromatic hydrocarbons, 
and arsenic). A healthy diet, especially rich in polyphenols 
such as epigallocatechin, curcumin, and resveratrol, is equ-
ally crucial in cancer prevention. It is essential to drink a lot 
of fluids, preferably water or green tea, reduce the intake 
of high-calorie, fatty foods, consume more fruits and vege-
tables rich in antioxidants, and make sure to supplement 
potential vitamin A and E deficiencies.
An important chemoprotective role is also played by 
nonsteroidal anti-inflammatory drugs; selective COX-2 in-
hibitors are particularly effective in this respect, but their 
toxicity means they can only be administered under strict 
medical supervision.
In light of the growing incidence rate of bladder cancer, 
it is crucial to take measures to protect the environment, 
reduce the concentrations of carcinogenic substances in 
air, drinking water, and food, as well as to use agents that 
boost the immune system, promote detoxification, and 
improve the state of the urothelium (the membrane that 
lines the bladder).
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